Mesoblast Launches Ryoncil® in U.S. for Pediatric SR-aGvHD

Story Highlights
  • Mesoblast Limited launches Ryoncil® in the U.S., the first FDA-approved MSC therapy.
  • Ryoncil® targets pediatric SR-aGvHD, with broad insurance coverage and patient access support.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Mesoblast Launches Ryoncil® in U.S. for Pediatric SR-aGvHD

An announcement from Mesoblast Limited ( (AU:MSB) ) is now available.

Mesoblast Limited has announced the commercial availability of Ryoncil® (remestemcel-L) in the United States, marking a significant milestone as the first FDA-approved mesenchymal stromal cell (MSC) therapy for any indication. Ryoncil® is designed to treat pediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD), a condition with high mortality rates. Mesoblast has established a patient access hub, MyMesoblast™, to assist with insurance coverage and financial assistance, ensuring broad access to this potentially life-saving therapy. The company is actively engaging with insurers to expand coverage, with nine commercial payers already on board, covering approximately 37 million lives in the U.S. This development reflects Mesoblast’s commitment to delivering innovative cellular medicines to patients in need.

More about Mesoblast Limited

Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell therapy technology platform to create therapies that release anti-inflammatory factors, targeting multiple arms of the immune system to reduce inflammation. Mesoblast is committed to expanding its cell therapies for various indications and has established commercial partnerships in Japan, Europe, and China.

YTD Price Performance: -37.73%

Average Trading Volume: 244,610

Technical Sentiment Signal: Sell

Current Market Cap: $1.76B

For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App